Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)

R. Advani, G. Visani, D. Milligan, H. Saba, M. Tallman, J. M. Rowe, P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis, E. Paietta, M. Litchman, A. Covelli, B. Sikic, P. Greenberg

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences